Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer
- Conditions
- Rectal Neoplasms
- Registration Number
- NCT05871762
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 3705
- pathologically confirmed rectal adenocarcinoma
- located within 12cm below the anal verge
- diagnosed with distant metastasis
- multiple primary colorectal cancers
- history of previous malignant tumors
- Pregnant or lactating women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year OS 3 years 3-year overall survival
- Secondary Outcome Measures
Name Time Method 3-year DFS 3 years 3-year disease-free survival
3-year LR 3 years 3-year local recurrence rate
adjuvant therapy rate at the time point of 3-year follow up the percentage of patients who underwent standard adjuvant therapy
EUS/MRI assessment rate at the time point of surgery of the primary lesion the percentage of patients who underwent standard rectal EUS/MRI assessment
3-year distant metastasis rate 3 years 3-year distant metastasis rate
neoadjuvant therapy rate at the time point of surgery of the primary lesion the percentage of patients who underwent standard neoadjuvant therapy
R0 resection rate at the time point of surgery of the primary lesion the percentage of patients who underwent R0 resection
CCR immediately after the completion of neoadjuvant therapy assessment Clinical Complete Response
pCR immediately after the completion of surgery Pathologic Complete Response
30-day mortality 30 days after the surgery death occurring within 30 days of the surgery
Trial Locations
- Locations (1)
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China